Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies with an alarming resistance to both chemotherapeutics and targeted therapy approaches. Genetically engineered mouse models (GEMM) of PDAC reflect molecularly and pathophysiologically the carcinogenesis and cancer progression observed in humans, thus being excellent tools for preclinical evaluation of new therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
